SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TOSHI

TOSHI.X is trending amid discussions about a recent price pump and its potential for further gains, driven by a partnership with Coinbase. Community members are actively debating ideal entry and exit points, as well as future exchange listings with some also expressing concerns about the pump's sustainability and the price action on Coinbase. Bullish sentiment remains around TOSHI as the face of Base.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU.X is trending as its community rallies around real-world brand building and a strong commitment to organic growth. Community members are highlighting the project's expanding ecosystem, from energy drinks to real-world events, and its dedicated holder base. The community's unwavering enthusiasm and ongoing initiatives are fueling positive sentiment despite market fluctuations.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media is trending amid heated online debates surrounding political violence and the upcoming election, with community members actively discussing the implications of the Charlie Kirk shooting and the potential release of the Epstein files. The stock is also drawing attention as users analyze its performance in light of broader economic concerns and potential shifts in the political landscape. Discussions cover topics ranging from free speech to government overreach.

StableX Technologies, Inc. engages in the design, development, manufacture, and sale of compact electric fleet solutions for use within urban and short-haul markets. It offers the AYRO 311 and Club Car 411 models. The company was founded on May 19, 2016 and is headquartered in New York, NY.

StableX Technologies Inc.

StableX Technologies, Inc. 

SBLX is trending due to speculation around its potential in the stablecoin industry, particularly following news of a $100M investment plan. Community members are actively discussing the low float and potential for a short squeeze, drawing comparisons to other recent high-flying crypto plays. Some are wary, citing the company's history and rebranding from AYRO, while others see potential for significant gains.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

QBTS is trending as the quantum computing sector gains momentum, with community members highlighting D-Wave's commercial applications and potential for acquisition by a tech giant. Some investors believe the stock is undervalued compared to its peers, while others are anticipating news from upcoming events like Qubits Japan to act as a catalyst. Discussions also involve potential short squeezes and the impact of interest rate decisions on the stock.

Presidio Property Trust, Inc. is a self-managed real estate investment trust, which invests in a diverse multi-tenant portfolio of real estate assets. It operates through the following segments: Office and Industrial Properties, Model Home Properties, and Retail Properties. The Office and Industrial Properties segment consists of office buildings and an industrial property leased to a variety of tenants ranging from small businesses to large public companies. The Model Home Properties segment consists of model home residential properties leased to homebuilders. The Retail Properties segment includes shopping centers. The company was founded by Jack Kendrick Heilbron on September 28, 1999 and is headquartered in San Diego, CA.

Presidio Property Trust Inc - Ordinary Shares - Class A

Shares of SQFT are surging, fueled by discussions of a potential short squeeze and low float speculation within trading communities. The stock's price action and volatility have captured attention, with some traders pointing to technical setups and prior analyst ratings as further justification for bullish sentiment. However, some caution that the rally may be short-lived due to dilution from a recent offering at $12.

FG Nexus, Inc. engages in the provision of reinsurance, asset management and merchant banking services. The company was founded in October 2012 and is headquartered in Charlotte, NC.

FG Nexus Inc.

Fundamental Global Inc.

FGNX is trending due to shareholder approval of a massive share increase aimed at accumulating Ethereum, sparking community debate around potential dilution and strategic direction. The approval of a distribution payment and share repurchase program adds to the mix of community speculation, with some questioning the company's long-term strategy amid high borrowing costs.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

NFLX is trending as investors discuss potential bids for WBD, with some speculating on the likelihood of a bidding war involving NFLX. Community members are also closely watching upcoming events like the Canelo fight, anticipating positive impacts on subscriber growth and market movement. Overall sentiment seems cautiously optimistic, balancing potential growth catalysts against broader market uncertainties.

Sui is an innovative layer-1 blockchain platform crafted to meet the demands of global adoption, providing a secure, robust, and scalable development environment. Rooted in a unique object-centric data model and fortified by the trusted Move programming language, Sui is engineered to tackle the inefficiencies found in current blockchain frameworks.  In addition to its solid technical underpinnings, Sui places a strong emphasis on user experience, aiming to remove common barriers encountered in blockchain interactions. Through groundbreaking features such as zkLogin, sponsored transactions, and programmable transaction blocks, Sui sets a new standard for user accessibility and friendliness within Web3 applications.  Unique elements of Sui Sui’s innovative architecture ensures swift transactions with stable fees and high throughput through horizontal scaling. Its object-oriented design offers deep composability for developers, enabling tailored object types with network-wide compatibility. This revolutionizes asset and protocol collaboration, fostering product innovation.  The platform's object-oriented approach dramatically improves transaction processing, enabling parallel execution and faster completion times. Additionally, unique consensus requirements expedite transaction finalization while maintaining stability. Sui prioritizes overcoming Web3 adoption barriers, offering native tools like zkLogin and sponsored transactions for wallet onboarding and fee management.  Move integration into Sui's data model combines innovation with security, mitigating common exploits found in smart contract languages. This empowers developers and users with a secure and intuitive platform, accelerating the evolution of Web3 applications.  About the Sui token The SUI token serves four primary functions within the Sui ecosystem: Proof-of-stake participation - Sui implements a delegated proof-of-stake mechanism, rewarding honest behavior by validators and SUI token holders who stake with them. Gas fee payments - SUI tokens cover gas fees for executing transactions and storing data onchain. Application utility - SUI is a versatile asset, integral to various applications within Sui’s ecosystem, including decentralized exchanges, lending platforms, gaming, and more. Governance - The SUI token empowers holders to participate in on-chain voting on significant matters like protocol upgrades and platform changes, shaping the future of Sui.  Additionally, the Sui storage fund ensures fair compensation for validators by distributing stake rewards over time and covering storage costs for previously stored on-chain data. This tokenomic strategy promotes indefinite data storage while maintaining fair compensation for validators, fostering long-term sustainability.

SUI.X is trending as community members discuss its potential partnership with Google, with some touting it as the next Solana or Ethereum. Bullish sentiment is fueled by perceived undervaluation and anticipation of future rate cuts, while others point to strong on-chain activity and the potential for a major breakout. Discussions also revolve around SUIG, the only treasury on SUI, trading at a discount, and its potential to run like other successful treasuries.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending due to concerns around potential impacts from a formal ban in China, despite commentary suggesting the company has diversified revenue streams. The community is debating the significance of the ban, with some suggesting it's a negotiation tactic while others highlight the UK deal and AI infrastructure investments as offsetting factors. Broader discussions include the AI sector's growth potential and whether current valuations are justified, particularly given China's push for domestic chip development.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

VF Corp (VFC) announced on Monday that they have entered into a definitive agreement for Bluestar Alliance to acquire the Dickies brand for $600 million in cash.The company said that the transaction is expected to close by the end of calendar year 2025. Shares of VF Corp traded over 2% higher in Monday’s pre-market session.Retail sentiment on <a href="https://stocktwits.com/symbol/VFC">VF Corp</a> remained unchanged in the ‘bearish’ territory, with message volumes at ‘normal’ levels, according to data from Stocktwits.Dickies&nbsp;is an American brand that offers clothing primarily in the workwear and streetwear categories, with distribution in 55 countries. “Since 1922, Dickies&nbsp;has provided hard-wearing, long-lasting and comfortable clothes, cementing its status as a storied brand in performance workwear,” said Joseph Gabbay, CEO of Bluestar Alliance, a brand management firm.VF Corp’s CEO Bracken Darrell said he was “confident” that under Bluestar Alliance’s ownership, Dickies will continue to improve and realize its significant growth potential. “As I’ve said before, we continuously evaluate our portfolio and this transaction will enable us to bring our net debt level down and will be accretive to our growth on a pro-forma basis,” Darrell said.VF Corp has been undergoing a turnaround under Darrell, with the company having trimmed jobs and also looking to reduce costs by selling some brands. It is also seeing costs related to the Trump administration’s tariffs on global trading partners. In July, the company noted that the incremental annualized tariff impact would be between $100 million and $120 million, down from its prior estimate of $150 million.Shares of VF Corp have declined nearly 31% this year and have fallen over 18% in the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-shares-surge-elon-musk-purchases-stock-first-time-since-2020/chwwIvpRdUG">Tesla Shares Surge As Elon Musk Discloses First Stock Purchase In Open Market Since 2020: Report</a>

In this photo illustration, the VF Corporation company logo is seen displayed on a smartphone screen.

VF Corp To Sell Dickies Brand To Bluestar Alliance For $600M

VF Corp said that the transaction is expected to close by the end of calendar year 2025.

Equity

The Campbell’s Company (CPB) experienced multiple price target hikes from Wall Street on Thursday, with TD Cowen citing that the packaged food maker’s annual profit guidance was less negative than initially feared, due to an acceleration of cost savings and near-term tariff mitigation.TD Cowen raised its price target to $31 from $29 and maintained a ‘Hold’ rating, according to TheFly. The firm added that the company’s fourth-quarter results were all better than expected.Retail sentiment on <a href="https://stocktwits.com/symbol/CPB">Campbell’s</a> remained unchanged in the ‘bullish’ territory, with chatter at ‘extremely high’ levels, according to data from Stocktwits. The retail user message count on the stock jumped 175% in the last 24 hours, as of Thursday morning, and shares of the firm were down nearly 3% during midday trading.<figure class="image"><img style="aspect-ratio:806/96;" src="https://news.stocktwits-cdn.com/CPB_sentiment_png_a93adb3d63.webp" alt="CPB sentiment.png" width="806" height="96"><figcaption>CPB sentiment and message volume September 4, 2025, as of 1:50 pm ET | Source: Stocktwits</figcaption></figure>Bernstein also raised its price target on Campbell's to $39 from $38 and kept an ‘Outperform’ rating. The firm noted that Campbell's seems to be doing the right things to get the portfolio moving again, investing in brand support and innovation, and fueling these investments with stepped-up productivity improvements.On Wednesday, CEO Mick Beekhuizen stated that consumers remain cautious and are being intentional with their spending, a trend that is expected to persist amid price increases resulting from the Trump administration’s tariffs, which are anticipated to slow demand for goods across the discretionary and consumables categories.Bernstein added that while snack category dynamics remain sluggish, management expects this portfolio to stabilize by the second half of 2026, noting that it's encouraging to see the recent success of more premium products, such as Milano cookies.Campbell’s shares have declined nearly 22% this year and fallen over 36% in the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/giii-apparel-ceo-says-company-absorbing-some-tariff-costs/chwdfxyRdYz">G-III Apparel CEO Says Company Absorbing Some Tariff Costs To Stay Competitive, Gain Market Share</a>

Prego brand spaghetti sauce in glass jars. (Source: Getty Images)

Campbell’s Gains Wall Street Confidence With Multiple Price Target Hikes, Retail Chatter Surges

Bernstein raised its price target on Campbell's to $39 from $38 and noted that the company appears to be taking the right steps to revitalize the portfolio, investing in brand support and innovation.

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) on Wednesday said that it has approved Biogen Inc.’s (BIIB) Zuranolone to treat moderate or severe postnatal depression (PPD) in adults following childbirth.Postnatal depression is a type of depression that many parents experience after having a baby and is marked by feelings of sadness, irritability, anxiety, loss of interest, extreme fatigue, appetite changes, among others. One in every ten women is affected by postnatal depression within a year of childbirth, as <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.gov.uk/government/news/mhra-approves-zuranolone-to-treat-postnatal-depression-in-adults-following-childbirth">per </a>MHRA.Biogen’s Zuranolone, under the brand name Zurzuvae, is the first oral treatment for postnatal depression approved in the UK, the agency said.The drug comes as a capsule and should be taken orally at night with a fat-containing meal for 14 days. Common side effects of the medicine include memory impairment, confusion, and fatigue, among others.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BIIB">BIIB stock</a> trended within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended marketing authorization for Zurzuvae last month in the European Union. The drug was approved by the U.S. Food and Drug Administration in 2023. According to Biogen, an estimated 5-20% of women with a pregnancy experience symptoms of PPD in Europe.Zurzuvae was discovered by Sage Therapeutics Inc. (SAGE). In 2020, Biogen and Sage Therapeutics entered into a collaboration to jointly develop and commercialize Zurzuvae in the U.S. As part of the agreement, Biogen received exclusive rights to develop and commercialize Zurzuvae outside of the U.S., excluding Japan, Taiwan, and South Korea.In the second quarter, Biogen reported revenue of $46.4 million from Zurzuvae, up from $14.9 million in the corresponding quarter of 2024, driven by increased demand.BIIB stock is down by 10% this year and by about 32% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-suncar-technology-stock-rallying-today/chsUeO7RdlB">Why Is SunCar Technology Stock Rallying Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration the logo of Biogen is seen on a smartphone with the FDA logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)  

UK Regulator Approves Biogen’s Drug For Treating Postnatal Depression

Zuranolone is the first oral treatment for postnatal depression approved in the UK, the agency said. 

Sarepta Therapeutics, Inc. (SRPT) announced on Thursday that it has entered into agreements with investors to restructure about $700 million of debt.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-refinancing-approximately-700">said</a> it will exchange approximately $700 million in aggregate principal amount of its existing convertible notes due 2027 for roughly $602 million in new 4.875% convertible senior notes due 2030, up to approximately 6.7 million shares of its common stock, and about $123.3 million in cash.Although the company has managed to push back the maturity of the new debt to 2030, it is also offering cash and common stock to investors. A fear of a potential dilution appears to have disappointed investors. SRPT stock was down over 7% at the time of writing.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SRPT">SRPT stock</a> stayed within ‘neutral’ territory over the past 24 hours, while message volume remained at ‘low’ levels. The stock is among the top ten trending names on the platform.<figure class="image"><img style="aspect-ratio:569/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_21_at_10_26_20_AM_png_8591ecfd20.webp" alt="Screenshot 2025-08-21 at 10.26.20 AM.png" width="569" height="62"><figcaption>SRPT's Sentiment Meter and Message Volume as of 10:26 a.m. ET on Aug. 21, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism about the refinancing.<stembedurl>https://stocktwits.com/scaredmoneymakenomoney/message/626069691</stembedurl>CEO Doug Ingram said that the exchange marks an important progress in the company’s long-term financial strategy. "By extending the maturity of a meaningful portion of our convertible notes to 2030, we have completed a shareholder-friendly transaction that significantly enhances our balance sheet flexibility and strengthens our financial position,” Ingram said.Ingram also said that the company believes it is well-positioned to fully fund its pipeline and meet its near-term obligations.Bank of America said that the debt refinancing transaction "makes sense" as it helps mitigate some near-term concerns about the company's ability to meet its obligations. Still, the firm continues to think clarity on uptake of Elevidys from here will be needed to get more comfortable with the long-term outlook.Sarepta’s gene therapy, Elevidys, a medicine intended for the treatment of Duchenne muscular dystrophy (DMD), created safety concerns following the death of two patients after treatment earlier this year. Both non-ambulatory patients suffered from acute liver failure.Sarepta has now resumed shipments for ambulatory individuals after a temporary pause initiated in late July. The company is now working with the FDA on the safety labelling process and risk-mitigation approach for non-ambulatory individuals. Citi on Wednesday <a href="https://stocktwits.com/news-articles/markets/equity/citi-believes-fda-may-closely-watch-sarepta-safeguards-for-gene-therapy-in-non-ambulatory-dmd-patients/chsiUM2RdLP">said</a> that the U.S. Food and Drug Administration may take a “more comprehensive look” at the regimen devised by Sarepta for non-ambulatory patients.Last month, the company said that it had initiated immediate changes to reduce operating expenses, including a 36% workforce reduction and pipeline reprioritization, in a bid to meet its 2027 financial obligations.Following the crisis with the gene therapy, Sarepta also <a href="https://stocktwits.com/news-articles/markets/equity/analyst-says-sarepta-lost-credibility-by-exiting-arrowhead-at-a-loss/chsRn7vRdON">unwound</a> its equity position in Arrowhead Pharmaceuticals earlier this month, in less than a year of its investment.SRPT stock is down by 84% this year and by about 87% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/j-and-j-to-invest-2-billion-to-expand-manufacturing-in-north-carolina/chsSyKYRdig">This Pharma Giant Is Set To Invest $2B To Expand Manufacturing In North Carolina, And It Just Received A Price Target Hike From Citi: Do You Own It?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Sarepta Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Sarepta Just Got A Good Restructuring Deal For $700M Debt, But Stock Tumbles 7% – Here’s Why

Although the company has managed to push back the maturity of the new debt to 2030, it is also offering cash and common stock to certain investors as part of the deal.

Truist on Monday lowered its price target on Regeneron (REGN) to $812 from $940, citing concerns with the company’s Eylea drug. The firm, however, kept a ‘Buy’ rating on the shares.The near-term investor focus remains on Eylea and Eylea HD uptake, though Regeneron continues to deliver growth on its top and bottom line with Dupixent and Libtayo programs, the analyst told investors in a research note. On Stocktwits, retail sentiment around the stock trended in the ‘bearish’ territory over the past 24 hours, coupled with ‘low’ message volume.<figure class="image"><img style="aspect-ratio:1398/126;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_11_at_1_26_40_PM_png_155e98c160.webp" alt="REGN's Sentiment Meter and Message Volume as of 1:26 p.m. ET on Aug. 11, 2025 | Source: Stocktwits" width="1398" height="126"><figcaption>REGN's Sentiment Meter and Message Volume as of 1:26 p.m. ET on Aug. 11, 2025 | Source: Stocktwits</figcaption></figure> A user further opined that the range of $400-$450 is a good entry point for the stock.<stembedurl>https://stocktwits.com/Johny34211/message/624597691</stembedurl>Eylea is approved to treat vision-threatening conditions that impact patients, such as diabetic retinopathy (DR), macular edema following retinal vein occlusion (RVO), and wet age-related macular degeneration (wAMD). Eylea HD, meanwhile, is a version of the drug that requires fewer injections.<a href="https://stocktwits.com/symbol/REGN">Regeneron</a> maintains exclusive rights to Eylea and Eylea HD in the U.S. Bayer has licensed the exclusive marketing rights outside of the U.S., where the companies share equally the profits from sales of the two products. In the second quarter, total Eylea U.S. net sales decreased 25% to $1.15 billion, while Eylea HD U.S. net sales increased 29%.The company also said that it expects its regulatory approvals to be delayed for its currently pending U.S. Food and Drug Administration applications for Eylea HD, which were supposed to be decided on by August 2025.The anticipated delay, the company said, is related to observations from an FDA general site inspection at the filler for Eylea HD in these regulatory applications, Catalent Indiana LLC. This inspection was completed in mid-July and was not specific to Eylea HD. Novo Nordisk recently acquired Catalent.The company, however, expressed optimism for a quick resolution of the filling issues for Eylea HD, citing its progress with alternate third-party fillers and Novo Nordisk’s communications with the FDA.According to data from Koyfin, 16 of 24 analysts covering Regeneron rate it ‘Buy’ or higher, while seven rate it a ‘Hold,’ and one rates it a ‘Strong Sell.’The stock has an average price target of $708.91, representing an upside of about 28%.REGN stock is down by 22% this year and by about 51% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/novartis-drug-shows-improvement-in-sjogrens-disease-in-late-stage-trials/chrH2PLRde0">Novartis Drug Shows Improvement In Sjögren's Disease In Late-Stage Trials: Analyst Deems Data Positive For Zura Bio As Well</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Regeneron Pharmaceuticals company logo is displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

This Stock Has Tumbled 50% In One Year, Gets A Price Target Cut Today – But Retail Believes $400-450 Is A Good Entry Point

Truist, however, kept a ‘Buy’ rating on the shares.

Wells Fargo on Thursday raised its price target on Sarepta Therapeutics, Inc. (SRPT) to $50 from $48 after the company’s second-quarter earnings beat Wall Street expectations on Wednesday.Wells’ new price target of $50 implies nearly 208% upside potential from the stock’s closing price on Wednesday. The analyst kept an ‘Overweight’ rating on the shares.The firm reiterated its confidence in the Elevidys franchise, noting that it sees an intact benefit-risk for ambulatory patients and potential upside from future updates on the non-ambulatory side.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SRPT">Sarepta</a> remained unmoved within ‘neutral’ territory over the past 24 hours while message volume remained at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:627/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_07_at_11_16_43_AM_png_bbc7e903bf.webp" alt="SRPT's Sentiment Meter and Message Volume as of 11:15 a.m. ET on Aug. 7, 2025 | Source: Stocktwits" width="627" height="64"><figcaption>SRPT's Sentiment Meter and Message Volume as of 11:15 a.m. ET on Aug. 7, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the second-quarter sales number shows that the recent patient deaths did not undermine demand.<stembedurl>https://stocktwits.com/parbv/message/624138164</stembedurl>Another highlighted that Elevidys caters to a niche patient population not addressed by many others.<stembedurl>https://stocktwits.com/Bearcase/message/624132232</stembedurl>Sarepta’s gene therapy, Elevidys, a medicine intended for the treatment of Duchenne muscular dystrophy (DMD), created safety concerns following the death of two patients after treatment. Both non-ambulatory patients suffered from acute liver failure.Duchenne Muscular Dystrophy is a genetic disorder characterized by progressive weakness and chronic inflammation of the skeletal, heart, and respiratory muscles. The disease primarily impacts boys.Sarepta has now resumed shipments for ambulatory individuals after a temporary pause initiated in late July. The company is now working with the FDA on the safety labelling process and risk-mitigation approach for non-ambulatory individuals, CEO Doug Ingram said on Wednesday.For the second quarter, Sarepta reported total revenues of $611.1 million, above an analyst estimate of $531.04 million, owing to higher net product revenue of Elevidys. Adjusted and diluted earnings per share came in at $2.02, up from $0.43 in the corresponding quarter of 2024, and above an analyst estimate of $0.67.The company also said that it is on track to realize over $100 million in cost savings through the end of 2025 as part of the restructuring announced in July. SRPT stock is down by about 86% this year and by about 87% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/duolingo-stock-rockets-30-percent/chrm761Rd37">Duolingo Stock Rockets 30% And Retail Chatter Surges A Whopping 1,400% In 24 Hours: Here’s Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

This Pharma Stock Shot Up 8% Today, Gets A Price Target Hike From Wells Fargo: Here’s Why Retail Sees Opportunity

Wells’ new price target of $50 implies nearly 208% upside potential from the stock’s closing price on Wednesday. 

Sarepta Gets A Price Target Hike From Wells Fargo: Retail Highlights Consistent Demand For Elevidys

Shares of Sarepta Therapeutics Inc. (SRPT) traded 20% higher on Tuesday afternoon after the U.S. Food and Drug Administration (FDA) allowed the company to resume shipping Elevidys, its gene therapy for Duchenne muscular dystrophy, to children who are still able to walk.Elevidys is the first and only gene therapy approved in the U.S. for Duchenne muscular dystrophy, a rare and progressive condition that affects mainly boys and leads to loss of muscle function.Sarepta has been in a quagmire ever since the company reported the deaths of two patients treated with Elevidys from liver failure earlier this year.Sarepta had paused Elevidys' shipments last week to allow the FDA to complete a review of available safety information. The company is still in discussions with the FDA regarding an updated safety labeling on Elevidys. The pause on Elevidys for patients who cannot walk continues as the discussions linger on.On Monday, the company said that the death of an 8-year-old boy in Brazil was deemed unrelated to treatment with Elevidys by the FDA.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SRPT">SRPT</a> is trending in the ‘extremely bullish’ territory, while message volume jumped from ‘high’ to ‘extremely high’ levels over the past 24 hours.<figure class="image"><img style="aspect-ratio:1354/132;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_29_at_2_20_10_PM_png_e1c2ee7b01.webp" alt="SRPT's Sentiment Meter and Message Volume as of 2:30 p.m. ET on July 29, 2025 | Source: Stocktwits" width="1354" height="132"><figcaption>SRPT's Sentiment Meter and Message Volume as of 2:30 p.m. ET on July 29, 2025 | Source: Stocktwits</figcaption></figure>After the hold was lifted on Monday, several analysts expressed relief or more concerns. &nbsp;JPMorgan upgraded Sarepta to ‘Neutral’ from ‘Underweight’ with a $24 price target. The FDA's recommendation to remove the voluntary pause of shipments of Elevidys in ambulatory patients is a "clear win" for the company, the analyst said.Bernstein, meanwhile, believes "it is only a matter of time before we learn of a death in an ambulatory patient that is deemed to be Elevidys-related."BMO Capital noted that while the financial overhang is partially removed with the lift of the hold, it expects a certain "hesitancy" from physicians and patients for Elevidys treatment in the near term.Barclays analyst Gena Wang, meanwhile, upgraded Sarepta to ‘Equal Weight’ from ‘Underweight’ with a price target of $22, up from $10. The suspension removal "removes the worst-case scenario" of a sustained period of Elevidys being off the market, and major liquidity risk is removed for now, it said, while adding that it is looking at greater FDA clarity.SRPT stock is down by 86% this year and by about 89% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/lucid-signs-up-timothee-chalamet-as-global-brand-ambassador/choaPQFR5yV">Lucid Signs Up Timothée Chalamet As Global Brand Ambassador: Retail Terms It A Desperate Cash-Draining Move</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did Sarepta Stock Jump 20% On Tuesday? Here’s What JPMorgan, Bernstein, Barclays Said About Elevidys

JPMorgan upgraded Sarepta to ‘Neutral’ from ‘Underweight’ with a $24 price target.

Shares of Sarepta Therapeutics (SRPT) tumbled 14% on Friday after a patient reportedly died following treatment with one of the firm’s gene therapies, drawing concerns from Wall Street analysts.A company spokesperson <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-07-18/sarepta-says-another-patient-died-after-receiving-gene-therapy">told</a> Bloomberg that a 51-year-old patient died of acute liver failure last month in an early-stage trial of a gene therapy to treat limb-girdle muscular dystrophy. Limb-girdle muscular dystrophy (LGMD) is a group of genetic conditions causing progressive muscle weakness and wasting, primarily affecting the muscles around the shoulders and hips.The company is already under pressure following the death of two patients following treatment with its gene therapy for Duchenne Muscular Dystrophy called Elevidys earlier this year.Following the news, Morgan Stanley analyst Michael Ulz said that the news adds to the ongoing safety concerns and near-term uncertainty around <a href="https://stocktwits.com/symbol/SRPT">Sarepta</a>.Leerink, meanwhile, opined that Sarepta management, knowing of a limb-girdle muscular dystrophy patient death in the trial and not disclosing it when announcing a restructuring earlier this week, is "deeply troubling and further undermines credibility."The firm added that it is “deeply disappointed in management's repeated execution missteps."While this is the first patient death reported in a limb-girdle muscular dystrophy trial, it is the third death reported by Sarepta this year across its gene therapy programs, William Blair told investors in a research note. Blair pointed out that Sarepta did not disclose the third patient death in its recent business update, which it termed "unfortunate and concerning.”Last month, the U.S. Food and Drug Administration said that it is probing the death of two pediatric patients with Duchenne Muscular Dystrophy (DMD) following treatment with Elevidys. The agency said it is investigating the risk of acute liver failure with serious outcomes, including hospitalization and death, following Elevidys and is evaluating the need for further regulatory action.Earlier this week, the company announced that it would eliminate 500 jobs, or approximately 36% of its workforce, as part of a restructuring effort aimed at achieving $400 million in annual cost savings. Sarepta also stated that it has agreed to the FDA’s request to include a black box warning in the ELEVIDYS label for acute liver injury and acute liver failure, to address the agency’s concerns regarding the use of the therapy in DMD patients who can walk.The company has halted shipments of the therapy to patients who cannot walk and is in talks with the FDA regarding a possible resumption.On Stocktwits, retail sentiment regarding Sarepta is trending in “extremely bullish” territory at the time of writing, accompanied by “extremely high” message volume.<figure class="image"><img style="aspect-ratio:628/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_18_at_10_54_58_AM_png_8b22d77332.webp" alt="SRPT's Sentiment Meter and Message Volume as of 10:55 a.m. ET on July 18, 2025 | Source: Stocktwits" width="628" height="63"><figcaption>SRPT's Sentiment Meter and Message Volume as of 10:55 a.m. ET on July 18, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the company destroyed the possibility of profitability or partnerships with the recent news.<stembedurl>https://stocktwits.com/Daily_Trader87/message/621494983</stembedurl>SRPT stock is down over 85% this year and by 87% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/retail-chatter-on-bmy-doubles-in-24-hours-with-drug-failing-to-meet-primary-goal/ch8kA37R5qZ">Retail Chatter On BMY Doubles In 24 Hours With Drug Failing To Meet Primary Goal: Here's What Investors Are Thinking</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Sarepta Draws Wall Street Ire After Third Patient Death This Year: Analyst Says ‘Deeply Concerning’ The Incident Wasn’t Reported Earlier 

A company spokesperson told Bloomberg that a 51-year-old patient died of acute liver failure last month in an early-stage trial of a gene therapy to treat limb-girdle muscular dystrophy.

Regeneron Pharmaceuticals, Inc. (REGN) on Wednesday announced that the U.S. Food and Drug Administration has granted accelerated approval for its Lynozyfic to treat adult patients with relapsed or refractory (R/R) multiple myeloma.The drug is now <a target="_blank" rel="noopener noreferrer nofollow" href="https://newsroom.regeneron.com/news-releases/news-release-details/lynozyfictm-linvoseltamab-gcpt-receives-fda-accelerated-approval">approved</a> in the U.S. for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti‑CD38 monoclonal antibody.Multiple myeloma is the second most common blood cancer. According to Regeneron, there are over 187,000 new cases of the cancer diagnosed globally every year, with more than 36,000 diagnosed and 12,000 deaths anticipated in the U.S. in 2025.The disease is characterized by the proliferation of cancerous plasma cells that crowd out healthy blood cells in the bone marrow, infiltrate other tissues, and cause potentially life-threatening organ injury.Shares of <a href="https://stocktwits.com/symbol/REGN">Regeneron</a> jumped 2% on Wednesday afternoon.While Lynozyfic was granted accelerated approval based on the LINKER-MM1 trial in which patients experienced a 70% objective response rate, continued approval may depend upon verification and description of clinical benefit in a confirmatory trial, the company said.George D. Yancopoulos, Chief Scientific Officer of Regeneron, said that the company is advancing its program for Lynozyfic, exploring its use in earlier lines of treatment as monotherapy and in novel combinations.On Stocktwits, retail sentiment around Regeneron is trending in the ‘bearish’ territory over the past 24 hours while message volume remained at ‘low’ levels.<figure class="image"><img style="aspect-ratio:625/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_02_130755_png_5f1153bfc5.webp" alt="REGN's Sentiment Meter and Message Volume as of 1:05 p.m. ET on July 2, 2025 | Source: Stocktwits" width="625" height="60"><figcaption>REGN's Sentiment Meter and Message Volume as of 1:05 p.m. ET on July 2, 2025 | Source: Stocktwits</figcaption></figure>REGN stock is down by 23% this year and by about 48% over the past 12 months. &nbsp;Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/organon-stops-drug-development-for-endometriosis-pain-after-mid-stage-trial-fails/chF0qINRT60">Organon Drops Drug Development For Endometriosis Pain After Mid-Stage Study Fails To Show Results</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Regeneron’s Therapy For Blood Cancer Bags FDA Approval: REGN Stock Jumps

While Lynozyfic was granted accelerated approval based on response rate in the LINKER-MM1 trial, continued approval may depend upon verification and description of clinical benefit in a confirmatory trial, the company said.

Advisorshares Trust - AdvisorShares Dorsey Wright Short ETF -1x Shares

Cut 25 bps

Cut 50+ bps

No change

Hike 25 bps

It’s Fed Decision Week. Polymarket gives a 90% chance of a 25 bps cut. What’s your call? 
 
*Powered by Polymarket

DWSH
AdvisorShares Dorsey Wright Short ETF

Feed

News

Sentiment

Fundamentals

Info

Latest DWSH News

DWSH AdvisorShares Dorsey Wright Short ETF